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Subacute cutaneous lupus erythematosus (SCLE) is characterized by particular cutaneous man-
ifestations such as non-scaring plaques mainly in sunlight exposed parts of the body along with
specific serum autoantibodies (i.e. antinuclear antibodies (ANA), Ro/SSa, La/SSb). It is consid-
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Aromatase inhibitorsered either idiopathic or drug induced. The role of chemotherapeutic agents in causing SCLE
has been investigated with the taxanes being the most common anticancer agents. However,
recent data emerging point toward antiestrogen therapies as a causative factor not only for
SCLE but also for a variety of autoimmune disorders. This is a report of a case of a 42 year
old woman who developed clinical manifestations of SCLE after letrozole treatment in whom
remission of the cutaneous manifestations was noticed upon discontinuation of the drug. In
addition, an extensive review of the English literature has been performed regarding the associ-
ation of antiestrogen therapy with autoimmune disorders. In conclusion, Oncologists should be
aware of the potential development of autoimmune reactions in breast cancer patients treated
with aromatase inhibitors.
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patient with metastatic breast cancer treated with letrozole.Introduction
Aromatase inhibitors (AIs) (i.e. letrozole, anastrozole, exemes-
tane) are used in the treatment of hormone dependent breast
cancer. Their use may be complicated with cutaneous events
such as increased sweating, alopecia, dry skin, pruritus, and
urticaria, but also with a variety of rashes. The eruption of
SCLE may begin with papules, which either coalesce or
develop into annular erythematous lesions with slight scale
or into scaly psoriasiform lesions. In rare cases angioedema,
toxic epidermal necrolysis and erythema multiforme may be
observed [1,2]. To date, there have been a number of reports
of SCLE attributed to the use of antiestrogen therapy [3–7].
In addition, some chemotherapeutic agents have already been
reported to induce SCLE, including cyclophosphamide, dox-
orubicin, paclitaxel, bevacizumab, fluorouracil or capecitabine
with most prevalent the use of taxanes [8–12]. However, the
accurate mechanism of SLE phenomena and various autoim-
mune disorders caused by antiestrogen therapy remains to be
elucidated. In this article a patient with breast cancer treated
with letrozole who developed SCLE is reported. An extensive
search of the literature regarding the association between
endocrine treatment and SCLE or autoimmune disorder devel-
opment, was also attempted.Material and methods
All published papers were obtained through the PubMed data-
base, using the subsequent Medical Subject Heading terms:
‘‘autoimmunity AND cancer”, ‘‘autoimmune manifestations
AND endocrine treatment AND breast cancer”, ‘‘aromatase
inhibitors AND autoimmune diseases”, ‘‘lupus erythermatosus
AND aromatase inhibitors”. Furthermore, a manual search
and review of reference lists were carried out. Titles were
screened and studies were excluded if obviously irrelevant. Lit-
erature up to December 31, 2015 was included.
Case presentation
A 42 year old Caucasian woman with a past medical history of
heterozygous beta-thalassemia, photosensitivity and a family
history of a mother with systemic lupus erythematosus
(SLE), was diagnosed in December 2011 with metastatic breast
cancer (estrogen receptor positive, progesterone receptor nega-
tive and HER2 positive). She was first presented with anemiaand thrombocytopenia and the diagnosis was established fol-
lowing a bone marrow biopsy which revealed a metastatic ade-
nocarcinoma compatible with breast cancer. She was treated
with paclitaxel, trastuzumab and zoledronic acid till April
2012 with a significant improvement of her hematologic
indices. Since then she continued with trastuzumab, tamoxifen,
and zoledronic acid until July 2014 when progressive disease in
the abdomen, brain and lungs was confirmed. Whole brain
radiotherapy was provided and a second line chemotherapy
with carboplatin and paclitaxel was administered until early
December 2014. Partial remission in the abdomen and com-
plete response in the chest were found, while brain metastases
remained stable. She then went on letrozole, luteinizing hor-
mone – releasing hormone (LHRH) analog and trastuzumab.
Within the first weeks and after the initiation of hormonal
treatment, on late December 2014, an annular erythematous
psoriasiform rash in the arms was noticed. During her next vis-
its and being on the same treatment the rash deteriorated
necessitating local and systematic corticosteroids. In June
2015 due to hematologic progression treatment was altered
to the combination of trastuzumab, pertuzumab, and doc-
etaxel with discontinuation of letrozole. A month later the
patient was admitted to the oncology ward due to febrile neu-
tropenia following treatment. At the time of her admission
while she was kept on corticosteroids the skin rash was still
persisting (Fig. 1). A skin tissue biopsy was performed reveal-
ing non-specific interface dermatitis. No vasculitis was noticed.
A rheumatology consultation along with elevated serum ANA
(1/640), Ro52 and Ro60 titers established the diagnosis of
SCLE. The patient was then prescribed hydroxychloroquine
along with a gradual tapering of the corticosteroids. She con-
tinued her medication until October 2015 when she visited the
outpatient clinic. A full remission of the rash was then estab-
lished and the patient had normal values on her complete
blood count. A total body computed tomography (CT) was
scheduled in order to further evaluate her disease and decide
on her further antitumor treatment (Table 1).
Discussion
The major morphological characteristics of SCLE are annular,
non-scarring, papulosquamous or psoriasiform plaques with
Table 1 Time course of reported patient since diagnosis of breast cancer.
Date Fact
December 2011 Breast cancer diagnosis
December 2011–April 2012 Paclitaxel, Trastuzumab
April 2012–July 2014 Tamoxifen, Trastuzumab
July 2014–December 2014 Carboplatin, Paclitaxel, Trastuzumab
Early December 2014 Letrozole, LHRH, Trastuzumab
Late December 2014 Appearance of rash
January 2015–April 2015 Deterioration of rash
May 2015 Onset of corticosteroids
June 2015 Anemia, leukopenia, thrombocytopenia, persistence of rash
June 2015 Letrozole discontinuation, SCLE diagnosis and hydroxychloroquine
initiation with corticosteroid tapering
October 2015 Full remission of SCLE manifestations
722 G. Zarkavelis et al.distribution mainly to the sunlight exposed areas of the body
[13]. The autoimmune profile of SCLE may consist of positive
Ro/SSA or La/SSB antibody titles while most patients test
positive for antinuclear antibodies (ANA) [14]. Complete
blood count tests may reveal anemia, leukopenia, and throm-
bocytopenia while skin tissue biopsy indicates perivascular and
subepidermal inflammatory cell infiltration or vacuolar alter-
ation of the basal cell layer. Constitutional symptoms such
as malaise, fever and arthralgias may be present [8]. The diag-
nosis is confirmed with the conjunction of both clinical and
serological profiles, while full picture of SLE may be absent.
The treatment consists of therapy with corticosteroids both
systematic and locally while in some cases specific drugs such
as hydroxychloroquine may be prescribed depending on the
severity of the manifestations. In the case of drug induced
SCLE the clinical features and laboratory findings do not dif-
ferentiate from typical subacute SLE [15]. Consequently, drug-
induced SCLE must be of high suspicion when typical findings
of SCLE onset correlate with the induction of a new drug. A
mandatory discontinuation of the new drug should be consid-
ered [16].
Throughout the literature drug induced SCLE has been
described and associated with the use of thiazide diuretics,
angiotensin-converting enzyme (ACE) inhibitors, calcium
channel blockers, and taxanes, and most recently with antie-
strogen therapy [9,13,17]. The use of tamoxifen in three
patients and anastrozole in one patient resulted in the appear-
ance of SCLE [3,5]. There are also two cases in the current lit-
erature reporting the association between aminoglutethimide
and SLE in cancer patients [6,7]. Etherington et al. reported
a breast cancer case with a history of SLE who presented with
a flair of a lupus-like syndrome and subsequent remission of
her symptoms after switching her treatment from tamoxifen
to aminoglutethimide [7] (Table 2).
It must be pointed out that breast cancer itself may induce
the appearance of both serum autoantibodies and of clinical
manifestations of autoimmune paraneoplastic syndromes
[18]. The onset of the cutaneous presentations correlates with
the onset of malignancy and sometimes even before the tumor
is diagnosed. Complete remission of the skin manifestations
can be seen following successful treatment of the underlying
malignant disease [18–20].
The relationship between estrogens and rheumatic diseases
has been widely investigated. There have been a number of
studies showing that estrogens induce and androgens suppressthe phenomena of SLE-like disease in F1 and MRL/I pr mice
[21]. In addition, it has been proven that sex hormones have an
immunomodulatory role in rheumatic diseases [22]. Other
reports have also demonstrated that estrogens induced the pro-
duction of anti-dsDNA antibodies by circulating lymphocytes
in patients with active SLE and that antiestrogen therapy, in
particular tamoxifen, resulted in the reduction of IgG3 autoan-
tibodies in the sera of (NZB  NZW)F1 female mice amelio-
rating the course of SLE-like disease [21,23].
On the other hand, it seems that when circulating estrogen
levels are higher they can inhibit the function of neutrophils.
The use of AIs results in reduction of estrogen levels which
in turn, increases the function of neutrophils. The cells then
adhere to the blood vessel endothelium and provoke autoim-
mune vasculitis or vasculitis-like reactions [24,25]. To date
there have been reports of cutaneous vasculitis attributed to
the use of exemestane in three patients [1], while the use of
letrozole seems to have been responsible for inducing necrotiz-
ing leukocytoclastic small vessel vasculitis in a number of cases
[25–27]. However as Digklia et al. have reported the case of
leukocytoclastic vasculitis that was attributed to the use of
letrozole in a patient, did not recur when switch to exemestane
took place. Thus it would be reasonable to speculate that
idiosyncratic reaction of the patient rather than estrogen deple-
tion may have induced the onset of vasculitis [26]. In addition,
anastrozole was associated with the onset of pruritic
micropapular eruptions in a single case and cutaneous vasculi-
tis has also been attributed to the same medication in other
patients [27,2,28] (Table 3).
Furthermore, the association between rheumatoid arthritis
(RA) and the use of antiestrogen therapy has also been inves-
tigated. There are case reports of rheumatoid arthritis induc-
tion with the use of exemestane as well as accelerated
cutaneous nodulosis in a patient already diagnosed with
rheumatoid arthritis undergoing letrozole therapy [29–31].
Chen and Ballou have recently reported that the use of selec-
tive estrogen receptor modulators (SERMs) in women with
breast cancer diagnosis results in higher incidents of both
SLE and RA. The use of SERMS resulted in a statistically sig-
nificant risk of SLE and RA, while the use of AIs mainly
resulted in higher incidents of RA. On the contrary, the same
report comes to the conclusion that the use of AIs tends to
decrease the incidence of SLE although those results were
not statistically significant [32]. Furthermore, third generation
AIs suppress the differentiation of naı¨ve T-cells to regulatory
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Aromatase inhibitors induced autoimmune disorders 723T-cells with a concomitant increase in proinflammatory cytoki-
nes interferon-c (IFN-c) and interleukin-12 (IL-12). Specifi-
cally, anastrozole treatment was associated with an increased
expression of genes responsible for inflammatory processes in
hormone receptor positive breast cancer. In addition, the use
of SERMs has been associated with a reduction in the matura-
tion and activity of autoreactive B cells and immunostimula-
tory dendritic cells which in turn results in alleviation of
dermatomyositis symptoms [33].
The immunomodulatory function of AIs has also been
reported as a potential causative mechanism leading to arthral-
gias and arthritis like syndromes [34]. Aminoglutethimide can
result in increased natural killer (NK) cell activation whereas
the use of formestane, a second generation AI, causes elevation
of IL-2 and INF-c levels. Reports of lymphocyte count reduc-
tion in patients being on exemestane, a steroidal AI, and a
blockage in the balance of IgG2a/IgG1 have been described
[33]. Consequently, apart from the aforementioned correlation
between the use of aromatase inhibitors and SLE or SLE-like
syndromes, the use of AI has been associated with the induc-
tion of arthralgias. Women on this type of antiestrogen ther-
apy often come up with symmetrical joint pains, morning
stiffness which resolves with exercise, mainly of the wrists
but also in other joints of the body. Carpal tunnel syndrome
is also a notable manifestation while on AI. These symptoms
can lead to discontinuation of the AI therapy in a significant
proportion of the patients [35,36]. Their relationship with
immune disorders such as sicca syndrome, systemic sclerosis
and Sjogren syndrome has also been investigated with the lat-
ter being more prevalent as reported by Laroche et al. Among
twenty-four women investigated for joint pain, nineteen were
found to have inflammatory pain of the joints and two had
inflammatory laboratory profile. Ten patients were diagnosed
with sicca syndrome of the eyes or mouth, one was diagnosed
with Sjogren syndrome, one RA, and another Hashimoto thy-
roiditis and seven more were considered to have probable Sjo-
gren syndrome [37,38].
Many theories have been proposed in order to explain the
mechanism leading to arthritis manifestations such as the noci-
ceptive role of estrogens and the subsequent increased sensitiv-
ity to pain stimuli following antiestrogen therapy [39]. The
increased activation of vitamin D receptor attributable to
antiestrogens leads to decline of vitamin D levels causing
arthralgias [40]. However, the immunomodulatory theory
remains a plausible explanation. It seems that the aforemen-
tioned increased plasma levels of proinflammatory cytokines
have a significant role in the induction of arthritis or arthritis
like syndromes. Furthermore, evidence exists concerning the
expression of aromatase in synovial cells which is then inhib-
ited by the use of AI thus resulting in high intrasynovial levels
of IL-6 leading to inflammation of the joints. In addition, the
upregulation of RANK ligand on osteoblasts induces the func-
tion of osteoclasts causing bone desorption. In one study,
women on immunotherapy with thymosin a1, as a part of their
arthralgia therapy, have been reported to measure lower serum
levels of INF-c, thus experiencing alleviation of their symp-
toms [41]. Furthermore recent data concerning muscoskeletal
pain induced by the use of AIs have emerged. Hershman
et al. have concluded that the use of omega-3 fatty acids which
were speculated to have an anti-inflammatory role failed to
improve the patients symptoms above placebo. The use of
omega-3 fatty acids in women suffering from arthralgias while
724 G. Zarkavelis et al.on AIs resulted in decreased triglyceride levels while there was
no difference in symptoms alleviated by the use of omega-3
fatty acids or placebo [42]. Finally, the correlation between
autoimmune manifestations and AIs extends even to the induc-
tion of autoimmune hepatitis. Throughout the literature there
are two case reports of female patients who developed autoim-
mune hepatitis with positive serum screening profile and com-
patible liver biopsy findings after the initiation of anastrozole
for their breast cancer [43,44]. Recent data suggest a tight cor-
relation of drug induced cutaneous lupus erythematosus with
immunogenic predisposing of the patient HLA subtype. Most
cases of drug induced lupus typically occur in patients with his-
tory of personal or family photosensitivity and it has been
demonstrated that most of the culprit drugs usually cause pho-
tosensitivity reactions [45].Conclusions
To our knowledge, there is a conflict regarding the use of AIs
and subsequent SCLE or SLE prevalence. So far, some data
suggest that antiestrogen therapy may have beneficial effects
in patients with SLE, while there are studies showing increased
incidence of rheumatic diseases with the use of both SERMS
and AIs [33]. Consequently, more research should be con-
ducted in order to elucidate the autoimmune adverse effects
induced by hormonal agents in patients with breast cancer.
Finally, clinicians must be alert of the correlation between
endocrine therapy and the wide spectrum of rheumatic
disorders.
This patient, who has been under surveillance and treat-
ment since 2011, underwent sequential therapies with taxane
consisting agents, anti-HER2 agents, platinum analogs, bis-
phosphonates without any skin disorders. As soon as letrozole
was initiated, a distinct skin entity emerged which did not com-
pletely disappear despite treatment with corticosteroids. Skin
rash disappeared only when letrozole was discontinued. In
addition, past medical and family history of this patient must
be taken into consideration regarding previous photosensitiv-
ity and mother’s SLE diagnosis.Conflict of Interest
The authors have declared no conflict of interest.Compliance with Ethics Requirements
All procedures followed were in accordance with the ethical stan-
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